AI-authored books about ADHD ‘for sale on Amazon'

Amazon has been accused of allowing AI-authored books about ADHD to be sold on its platform.
The online marketplace has been targeted by those looking to sell cheap-to-publish books written by artificial intelligence, which can include unhelpful or dangerous misinformation.
Chatbots now appear to be writing books about the condition, according to The Guardian.
Originality.ai, a US company that detects content produced by AI, analysed samples from eight books obtained by The Guardian.
The firm then awarded a rating of 100 per cent to each of the samples for its AI detection score, effectively confirming it was highly confident that the books were written by a chatbot.
Texts highlighted by the newspaper as being suspected AI-authored reads include Navigating ADHD in Men: Thriving with a Late Diagnosis and Men with Adult ADHD: Highly Effective Techniques for Mastering Focus, Time Management and Overcoming Anxiety.
It comes after AI were accused of copying a Holocaust survivor's memoir last week.
Other robot-written texts have included mushroom-foraging books, travel guides and weight-loss recipe books.
Michael Cook, a computer science researcher at King's College London, told The Guardian that it was 'frustrating and depressing to see AI-authored books increasingly popping up on digital marketplaces' particularly on health and medical topics, which could result in misdiagnosis or worsen conditions.
Yet he added that Amazon's business model incentivised this kind of practice as it made 'money every time' shoppers purchased books, regardless of whether the work was 'trustworthy or not'.
An Amazon spokesman told The Guardian: 'We have content guidelines governing which books can be listed for sale and we have proactive and reactive methods that help us detect content that violates our guidelines, whether AI-generated or not. We invest significant time and resources to ensure our guidelines are followed and remove books that do not adhere to those guidelines.
'We continue to enhance our protections against non-compliant content and our process and guidelines will keep evolving as we see changes in publishing.'
High-profile artists have repeatedly warned of the threat AI poses to the UK's creative industries.
More than 1,000 artists have urged ministers to abandon plans to allow their work to be used in the training of AI models.
Last month, Abba's Bjorn Ulvaeus joined the row over government plans to water down copyright laws for the benefit of big tech companies.
Speaking to The Times, the Swedish star said: 'Copyright is the oxygen which creators and the creative economy depend on for their existence and survival.
'They cannot be sacrificed. Unfortunately, there is an alternative and, in my opinion, more dangerous view, driven by profit-seeking tech companies. That view favours a weaker rights framework and broad exceptions to copyright.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

傳蘋果將捨棄Google合作 將收購AI搜尋黑馬Perplexity

科技中心／李宜樺報導 ▼▲蘋果傳新併購消息！恐捨棄Google，轉密會AI搜尋新星Perplexity。（圖／翻攝自YT@Apple） AI戰升溫，科技巨頭火力全開！繼Meta投資Scale AI後，如今傳出蘋果也悄悄布局，要收購AI搜尋新貴「Perplexity AI」，甚至傳出考慮放棄Google作為預設搜尋引擎。這場看似平靜的搜尋戰場，已悄然掀起風暴！ 根據《彭博》知名科技記者Mark Gurman爆料，蘋果併購部門主管Adrian Perica已在內部討論是否收購Perplexity，雖仍處於早期階段，但若交易成真，將是蘋果史上最大規模併購案──該公司估值高達140億美元，遠超2014年30億美元收購Beats的紀錄。 除了併購，蘋果也考慮另一合作模式，將Perplexity整合至Safari與Siri，作為替代Google搜尋的AI解決方案。畢竟蘋果與Google的搜尋合作協議，正面臨美國反壟斷調查威脅，恐有被迫拆夥的可能。 Perplexity成立僅兩年，卻以AI驅動搜尋技術嶄露頭角，透過自動總結、引文標示等功能挑戰Google霸主地位，甚至已與三星展開深度合作，成為蘋果收購計畫的潛在障礙。 Perplexity對收購傳聞低調回應，稱「目前沒有相關消息」，但該公司近期與多家科技巨頭接觸頻繁，包括Meta也曾試圖收購、並挖角其CEO Aravind Srinivas，顯示AI搜尋市場人才爭奪戰已進入白熱化。 當AI搜尋成為下一代搜尋引擎的競爭主戰場，蘋果此舉無疑是對Google發出重大威脅。科技巨頭的版圖重組已開始，誰能掌握搜尋流量與AI技術，誰就能主宰未來。 更多三立新聞網報導2025報稅必知／報稅倒數9天 你真的報完了嗎？「這一步」沒做＝白報！美軍參戰 介入以伊戰爭！衝突升級 冷靜異常的黃金現補漲行情？全球熱錢瘋搶亞洲 高盛曝對沖基金5年最大買盤新光金、新壽5月再虧破百億 靠準備金撐盤仍難止血？

Yahoo

an hour ago

• Yahoo

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases. Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics. Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. He is a leading figure in the field of new therapeutic modalities, and has developed of a new class of therapeutics termed stapled peptides, enabling drug development against targets long considered undruggable. As an entrepreneurial leader, Professor Verdine has founded or co-founded over ten biotechnology companies, including five publicly listed entities: Enanta Pharmaceuticals (NASDAQ: ENTA), Tokai Pharmaceuticals (NASDAQ: TKAI), and Wave Life Sciences (NASDAQ: WVE), among others. One venture was acquired by a major pharmaceutical company, while others continue developing disruptive medicines with a special focus on oncology. Three therapeutics he spearheaded—romidepsin (Istodax®), paritaprevir (a component of Viekira Pak®), and glecaprevir (a component of Mavyret®) —have received FDA approval. Professor Verdine currently serves as a Venture Partner at Andreessen Horowitz (a16z), a role he previously held at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures. He was also a Special Advisor to Texas Pacific Group. His advisory engagements include top research institutions such as the U.S. National Cancer Institute and Harvard Medical School. "By integrating XtalPi's cutting-edge AI capabilities with decades of drug development expertise, we have a unique opportunity to deliver transformative therapies to patients worldwide," stated Professor Verdine. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc.

Yahoo

an hour ago

• Yahoo

Record-low price alert: Save $50 on the Samsung Galaxy Watch FE at Amazon

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. SAVE $50: As of June 17, the Samsung Galaxy Watch FE is on sale for $199.99 at Amazon. That's 20% off its list price of $249.99 and a return to its lowest-ever price. Opens in a new window Credit: Samsung Samsung Galaxy Watch FE $199.99 at Amazon $249.99 Save $50 Get Deal As we head into the summer, there are some great deals popping up at various retailers, with plenty of discounted smartwatches on offer. No matter if you're looking for a high-end option or something to just cover the basics, there are a lot of discounts available on various models. When it comes to the latter, one of our favorite budget-friendly picks that's on sale right now is the Samsung Galaxy Watch FE. Normally, the Samsung Galaxy Watch FE is listed for $249.99, but it's currently enjoying a 20% discount down to $199.99. What's even better is this marks a return to its lowest-ever price according to price tracker camelcamelcamel, so now is an excellent time to pick it up if it has been on your radar. SEE ALSO: Amazon announces Prime Day 2025 dates, and the 4-day rumors are true When it comes to features, the Samsung Galaxy Watch FE boasts a variety in the realm of health and fitness to help you out throughout the day. These include step counts, active minutes, how many calories you've burned, heart rate tracking, and sleep tracking, to name a few. It also has a BIA sensor that provides you with details on body fat, muscle mass, water levels, and more to help you with your fitness goals. There's no better time to pick up an item than when it's at its lowest-ever price, so don't miss out on the Samsung Galaxy Watch FE down to $199.99. There are a couple more smartwatch deals available right now that are worth checking out alongside this one. Also at Amazon, Apple's budget-friendly smartwatch, the Apple Watch SE 2, is on sale, and if you're looking for a stylish pick, the Garmin Lily 2 is discounted as well. Apple AirPods Pro 2nd Gen With MagSafe USB-C Charging Case — $169.00 (List Price $249.00) Roku Ultra 4K Ultimate Streaming Player (2024 Release) — $99.00 (List Price $99.99) Apple AirTag (4-Pack) — $74.99 (List Price $99.00) Samsung Galaxy Watch 7 (Wi-Fi, 40mm, S/M Green) — $199.99 (List Price $299.99)